TWST Twist Bioscience Corp Insider Trading

TWST CEO Emily Leproust sells 16,470 shares for $1,118,554.58 via scheduled 10b5-1 plan; retains 846,872 shares + 75,439 options.

Emily M. Leproust, TWST CEO, executed 4 separate open-market sales totaling 16,470 shares for $1,118,554.58 on 2026-05-28 under a pre-arranged 10b5-1 trading plan adopted 2025-05-27. Prices ranged from $65.33 to $68.61 (blended average $67.91), near the current price of $67.86 and well above the 52-week low of $23.30. This is a 1.9% reduction of her non-derivative holdings, leaving her with 846,872 shares post-transaction. The sale follows modest near-term stock strength (+12.4% over 30 days, +45.5% over 90 days) but occurs at a company trading 4.5% below its 52-week high of $71.04. TWIST remains unprofitable (latest quarter net income $-44.0M) despite revenue growth of +20.3% year-over-year and latest quarterly revenue of $110.7M. Her prior sales at TWST have shown mixed near-term results (30-day returns: -8.2%, -7.2%, -9.5%, +1.8%, -2.1%), and her cross-ticker track record shows average 90-day return of +7.5% after sells. The scheduled nature of this sale under her 10b5-1 plan means the timing reflects pre-planned portfolio management rather than a discretionary decision responding to current conditions.

TWST CEO Emily Leproust sold 49,299 shares for $3,213,653.17 via 10b5-1 plan; retains 846,872 shares plus 208,835 option holdings.

CEO Emily M. Leproust executed 3 separate sales totaling 49,299 shares for $3,213,653.17 (blended average price $65.19) on May 26–27, 2026, as part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-27. This is a scheduled, non-discretionary transaction. Post-sale, she retains 846,872 non-derivative shares and 208,835 shares in derivative holdings (option pools), representing a -5.5% reduction in her non-derivative position. The current price of $69.03 is above the sale prices ($65.08–$66.28), reflecting a 16.7% gain in the stock over the past 30 days and +47.1% over 90 days. While her prior sales at TWST show mixed results (three recent sells in April 2026 followed by 30-day declines of -8.2%, -7.2%, and -9.5%), the structured nature of the 10b5-1 plan removes discretionary timing from this decision and positions it as a pre-planned liquidity event. The company remains unprofitable (net income $-44.0M on latest full-year basis) despite 20.3% annual revenue growth.